Can-Fite BioPharma Ltd. (CANF) |
|
2.878 -0.032 (-1.1%)
|
06-06 14:22 |
|
Open: |
2.96 |
Pre. Close: |
2.91 |
|
High:
|
2.96 |
Low:
|
2.8212 |
|
Volume:
|
16,867 |
Market Cap:
|
12(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:17:04 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 3.46 One year: 4.05 |
| Support: |
Support1: 2.22  Support2: 1.75 |
| Resistance: |
Resistance1: 2.97 Resistance2: 3.46 |
| Pivot: |
2.46 |
| Moving Average: |
MA(5): 2.77 MA(20): 2.37
MA(100): 2.75 MA(250): 6.02 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 88.6 %D(3): 89.9 |
| RSI: |
RSI(14): 77.6 |
| 52-week: |
High: 11.19 Low: 1.51 |
| Average Vol(K): |
3-Month: 58 (K) 10-Days: 35 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CANF ] has closed below upper band by 5.3%. Bollinger Bands are 8.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.97 - 2.98 |
2.98 - 2.99 |
|
Low:
|
2.85 - 2.86 |
2.86 - 2.88 |
|
Close:
|
2.89 - 2.91 |
2.91 - 2.93 |
|
Company Description |
|
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. |
Headline News |
Mon, 05 Jun 2023
Pre-market Movers: FRZA, CJET, CIR, EVAX, DAWN… - Nasdaq
Thu, 01 Jun 2023
Can Fite Biofarmas Q1 Earnings Miss Estimated EPS by 1000 - Best Stocks
Thu, 01 Jun 2023
2023-06-01 | NYSEAM:CANF | Press Release | Can-Fite Biopharma ... - Stockhouse Publishing
Thu, 01 Jun 2023
Can-Fite Reports First Quarter 2023 Financial Results & Provides ... - Business Wire
Mon, 15 May 2023
Can-Fite: Presenting Namodenoson's New Pancreatic Cancer ... - Business Wire
Tue, 09 May 2023
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
